DNA methylation alteration is one of the most prominent epigenetic changes in cancer. Because DNA originated fromcancer cells is a stablemolecule that is easily detectable in clinical specimens such as blood, sputum, urine, and stool, DNA methylation alterations in tumorigeneses have become one of the promising candidate biomarkers for early detection, prognosis, therapeutic response prediction, and recurrence monitoring in cancer patients. Recent development of technologieshas allowed global genome-wide DNA methylation analysis in normal as well as in cancer cells and has provided extensive information for candidate biomarkers. Herein we summarize the features of DNA methylation in cancer, their suitability as DNA methylation biomarkers in comparison with others, and their status in applications of DNA methylation biomarkers in cancer. The research field of DNA methylation biomarking is evolving rapidly with promising results that have the potential to confer enormous benefits for cancer patients in the future.
|Title of host publication||Biomarkers in Disease|
|Subtitle of host publication||Methods, Discoveries and Applications: Biomarkers in Cancer|
|Number of pages||27|
|Publication status||Published - 2015 Jan 1|
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)